Funding agencies: Supported in part by the National Institutes of Health (RO1NS077851, RO1MH094741 to J.D.), the National Cancer Institute (RO1CA089054 to J.D.), Fondo de Investigaciones Sanitarias (FIS) (11/01780 to J.D.), and Fundació la Marató de TV3 (to J.D.).
Anti–N-methyl-D-aspartate-glutamic-receptor encephalitis presenting as paroxysmal exercise-induced foot weakness
Article first published online: 29 MAY 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 6, pages 820–822, June 2013
How to Cite
Labate, A., Quattrone, A., Dalmau, J. and Gambardella, A. (2013), Anti–N-methyl-D-aspartate-glutamic-receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. Mov. Disord., 28: 820–822. doi: 10.1002/mds.25510
Relevant conflicts of interest/financial disclosures: J.D. has a research grant from Euroimmun, and receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 25 JUN 2013
- Article first published online: 29 MAY 2013
- Manuscript Revised: 9 APR 2013
- Manuscript Accepted: 9 APR 2013
- Manuscript Received: 30 AUG 2012
Additional Supporting Information may be found in the online version of this article.
|mds25510-sup-0002-suppfigure1.jpg||2120K||Supplementary Figure 1. Panel shows (A) immunoreactivity of CSF of the patient (diluted 1:2) with a section of rat hippocampus giving the typical neuropil hippocampal reactivity seen with NMDAR antibodies, and (B) the reactivity with cultures of dissociated rat hippocampal neurons, demonstrating cell surface reactivity. In addition, the serum and CSF of the patient reacted with NR1 subunit of the NMDAR in a cell based assay (not shown here).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.